SEARCH OUR PAGES

Headlines

AACR Annual meeting (April 10-15, 2021), view our E-posters : CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy; BiCKI®-IL-7, bifunctional therapy targeting PD-1 and IL-7 bifonctionnel ciblant PD-1 et IL-7; OSE-230, novel monoclonal antibody agonist therapy.

A clinical-stage biotechnology company in immunotherapy

focused on developing and partnering therapies to control the immune system
for immuno-oncology and autoimmmune diseases.

4

Products in clinical-stage status

3

Partnerships with international pharma companies

50

High-level collaborators

OSE Immunotherapeutics,
a clinical-stage biotechnology company

focused on developing and partnering therapies to control the immune system
for immuno-oncology and autoimmmune diseases.

Collaborations and partnerships

A fundamental element of both long-term strategy and day-to-day operations

  • Scientific and Technological
    Platforms

    Neoepitopes,
    agonist or antagonist monoclonal antibodies

    +
  • Immuno-oncology

    T-cell activation through neoepitopes
    Transforming tumor microenvironment
    suppressive cells into effector cells

    +
  • Autoimmune Diseases

    Down regulating T effector cells to decrease immunological reactivity

    Up regulating regulatory
    T-cells to develop immune tolerance

    +
  • Partnerships

    Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need

    +

Our latest news

OSE Immunotherapeutics Announces First Peer-Reviewed…

DISCOVER +

OSE Immunotherapeutics Receives Authorization for…

DISCOVER +

OSE Immunotherapeutics Reports 2020 Financial…

DISCOVER +

OSE Immunotherapeutics and ARCAGY –…

DISCOVER +

To receive OSE Immunotherapeutics’ latest news

Agenda

Upcoming Events